Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Dermatologic 1

Conditions

Melanoma 5Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 10Nivolumab 5Gemcitabine 4durvalumab 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cryosurgery 3Cisplatin 3Blood Specimen Collection 3tremelimumab 2temsirolimus 2pertuzumab 2pegilodecakin 2enzalutamide 2cabozantinib 2alvocidib 2Vorinostat 2Trastuzumab 2Ritonavir 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Interleukin-2 2Cyclophosphamide 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Hydroxychloroquine × Dermatologic × Clear all
NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡